Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
View ORCID ProfileLuis Rosero-Bixby
doi: https://doi.org/10.1101/2021.11.08.21266087
Luis Rosero-Bixby
Universidad de Costa Rica, Centro Centroamericano de Población (CCP)
Roles: Emeritus Professor

Data Availability
All data produced in the present work are contained in the manuscript (Appendix table)
Posted November 09, 2021.
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
Luis Rosero-Bixby
medRxiv 2021.11.08.21266087; doi: https://doi.org/10.1101/2021.11.08.21266087
Subject Area
Subject Areas
- Addiction Medicine (215)
- Allergy and Immunology (495)
- Anesthesia (106)
- Cardiovascular Medicine (1095)
- Dermatology (141)
- Emergency Medicine (274)
- Epidemiology (9765)
- Gastroenterology (480)
- Genetic and Genomic Medicine (2308)
- Geriatric Medicine (222)
- Health Economics (462)
- Health Informatics (1557)
- Health Policy (734)
- Hematology (236)
- HIV/AIDS (503)
- Medical Education (237)
- Medical Ethics (67)
- Nephrology (257)
- Neurology (2141)
- Nursing (134)
- Nutrition (336)
- Oncology (1175)
- Ophthalmology (364)
- Orthopedics (128)
- Otolaryngology (220)
- Pain Medicine (146)
- Palliative Medicine (50)
- Pathology (311)
- Pediatrics (695)
- Primary Care Research (266)
- Public and Global Health (4653)
- Radiology and Imaging (776)
- Respiratory Medicine (623)
- Rheumatology (274)
- Sports Medicine (210)
- Surgery (251)
- Toxicology (43)
- Transplantation (120)
- Urology (94)